CVKDCash now, dilution later
Cadrenal Therapeutics says it’s raising up to about $8.8 million in a private placement under Nasdaq rules. The math is pretty simple: $3 million comes in upfront, and another roughly $5.8 million could show up if the warrants get exercised in full.
Why this matters
For a small biotech, cash is oxygen. Deals like this can keep the lights on and fund the next stretch of the road, but they also usually mean existing shareholders get a smaller slice of the pie.
The investor takeaway
- Upfront proceeds: $3 million
- Potential additional proceeds from warrants: about $5.8 million
- Total possible gross proceeds: up to $8.8 million
Big picture: this is a classic biotech balancing act — raise enough money to keep the pipeline moving, but try not to hand shareholders too much of the dilution hangover.